InterVene’s First‑of‑Its‑Kind Recana® Thrombectomy System Gains FDA Clearance
InterVene, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration for its Recana® Thrombectomy Catheter System, intended for the treatment of venous in-stent restenosis and native vessel obstructions.
The privately held company focuses on developing devices to treat venous occlusions, which can cause serious long-term complications if not properly managed.
Recana is the first fully integrated system designed specifically for challenging venous procedures.
It includes a debulking catheter, introducer and collection sheaths, and nitinol baskets to capture thrombotic material. The system aims to simplify treatment and support improved outcomes for patients.
The technology is engineered to enable single-session treatment and reduce the need for multiple devices.
A stainless-steel helical coring element with a sharp bevel is used to remove stubborn residual blockages, while a spiral nose cone helps cross obstructed areas.
The nitinol baskets are deployed in the lower limbs to collect material removed during the procedure, helping streamline workflow.
InterVene expects the system to address limitations of traditional recanalisation techniques and provide a more efficient approach to managing venous stent obstruction, a common complication following deep venous stent placement.